Home Latest Articles
Latest Articles
  • Chen HUANG, Hong TANG
    World Clinical Drug. 2023, 44(11): 1207-1210.
    Objective

    To study the relationship between traditional Chinese medicine (TCM) syndromes of diabetes mellitus type 2 (T2DM) and free fatty acid (FFA), tumor necrosis factor (TNF)-α and vascular endothelial growth factor (VEGF), and summarize the relationship between laboratory indexes and TCM syndrome types of T2DM.

    Methods

    A total of 300 patients with T2DM were collected from the outpatient and inpatient department of endocrinology of LongHua hospital affiliated to Shanghai university of TCM from January 2019 to March 2020, including 65 cases of Qi and Yin deficiency syndrome, 65 cases of damp heat trapped spleen syndrome, 50 cases of Yin deficiency and heat excess syndrome, 55 cases of Yin and Yang deficiency syndrome, and 65 cases of blood stasis venation syndrome. The relationship between each syndrome group and FFA, TNF-α and VEGF was measured and observed.

    Results

    TNF-α in blood stasis venation syndrome group was significantly higher than those of Qi and Yin deficiency syndrome group, damp heat trapped spleen syndrome group, Yin deficiency and heat excess syndrome group and Yin and Yang deficiency syndrome group (P<0.05). The levels of VEGF in damp heat trapped spleen syndrome group and blood stasis venation syndrome group were significantly higher than those in Qi and Yin deficiency syndrome group, Yin and Yang deficiency syndrome group and Yin deficiency and heat excess syndrome group (P<0.05). The level of FFA in blood stasis venation syndrome group was higher than those in Qi and Yin deficiency syndrome group and Yin and Yang deficiency syndrome group, and the difference were statistically significant (P<0.05).

    Conclusion

    FFA, TNF- α and VEGF are closely related to blood stasis venation syndrome and damp heat trapped spleen syndrome of T2DM, but they are not sensitive indexes for early diagnosis of syndrome types of T2DM related complications.

  • Guanghua WU, Congcong YAN, Yabing XING
    World Clinical Drug. 2023, 44(11): 1211-1214.
  • Jianhua XU, Shiya WANG
    World Clinical Drug. 2023, 44(11): 1215-1218.

    Sotagliflozin is a drug with dual inhibitory effects on sodium-dependent glucose transporters (SGLT) 1 and 2. Inhibition of SGLT1 can inhibit glucose and galactose absorption in the digestive tract, and inhibition of SLGT2 can reduce glucose reabsorption in the renal tubules. Sotagliflozin has been shown to be effective in the treatment of type 2 diabetes mellitus. In recent years, it has shown great potential in cardiovascular diseases. Soglitazone can reduce adverse cardiovascular events in type 2 diabetes patients with cardiovascular risk factors. This article summarized the research on the application of sotagliflozin in diabetes mellitus complicated with cardiovascular diseases at home and abroad in recent years, in order to provide guidance for the further application of sotagliflozin in cardiovascular diseases.

  • Dingxin KE, Yi WANG, Min SUN, Yajun JIANG, Kaiyun LIU
    World Clinical Drug. 2023, 44(11): 1219-1225.

    Polyinosinic polycytidylic acid is an artificially synthesized double stranded ribonucleic acid that is recognized by Toll-like receptor 3, induces innate and adaptive immune responses. It is generally considered as a type Ⅰinterferon inducer, antiviral and anti-tumor immunomodulator agent, and also an effective vaccine adjuvant, and has shown great potential in the treatment of diseases. Therefore, this article reviewed the regulatory mechanism, safety, and the research progress of polyinosinic polycytidylic acid as an immunologic agent in clinical practice, hoping to provide useful reference for the follow-up research of polyinosinic polycytidylic acid.

  • Ruling ZHENG, Jianzhong SHENTU
    World Clinical Drug. 2023, 44(11): 1226-1231.

    B cell lymphoma (Bcl)-2 gene is mainly expressed in the outer mitochondrial membrane. It is the major regulator in the apoptotic signaling pathway, and its aberrant expression is closely related to tumor development. Bcl-2 protein, encoded by Bcl-2 gene, regulates apoptosis through protein-protein interactions and has become an important target for the treatment of chronic lymphocytic leukemia (CLL). Most of the Bcl-2 inhibitors are small molecule compounds. Fragment-based drug design approaches that mimic the BH3 structural domain of the Bcl-2 protein have driven the development of Bcl-2 inhibitors. The currently marketed Bcl-2-targeted inhibitor drug venetoclax can effectively treat CLL and small lymphocytic leukemia, and shows better clinical efficacy in B-lymphocyte malignancies, and other Bcl-2 inhibitor drugs that have entered clinical studies also show better development prospects. This article reviewed the mechanism of Bcl-2, and summarized the research progress of Bcl-2 inhibitors in recent years, to provide insights for the further development of Bcl-2 inhibitors.

  • Huihui XUE, We YUE
    World Clinical Drug. 2023, 44(11): 1232-1237.

    Epileptic seizure induced by antipsychotic drugs is a problem that needs attention in clinical use. Current evidence shows that the risk of seizure induced by first-generation antipsychotics is low, except chlorpromazine. Among second-generation antipsychotics, clozapine has the highest risk of seizure induction, while olanzapine, risperidone, quetiapine, ziprasidone, and aripiprazole have a lower risk. Many factors influence the threshold of antipsychotic-induced seizures, such as seizure history, concomitant use of other drugs that lower the seizure threshold, comorbidity with other chronic diseases (e.g. organic brain diseases), individual susceptibility, and age, among which the antipsychotic blood concentration being most closely associated with increased seizure frequency. To reduce the risk of seizures, antipsychotic drugs should be slowly titrated from a small dose during the initial treatment stage, monitor blood drug concentrations, and maintain the minimum effective dose. Electroencephalogram changes may accompany the administration of antipsychotic medications, but the relationship between the abnormal rate of electroencephalogram and seizure risk is not clear. It is important to note that although there is substantial evidence that antipsychotics can lower seizure thresholds, some antipsychotics can also exert antiepileptic effects. Therefore, this article reviewed previous literature to explore the relationship between antipsychotics and seizures.

  • Li ZHOU, Weizheng FENG, Yaping WANG, Chengyang LIU, Duan ZHOU
    World Clinical Drug. 2023, 44(11): 1238-1242.

    Chronic heart failure (CHF) has a long course and repeated symptoms, which not only leads to poor quality of life, but also causes serious economic burden to society. There is a remarkable effect of traditional Chinese medicine (TCM) in the treatment of CHF. Professor Zhou Duan, a famous TCM doctor in Shanghai, a lifetime professor in Longhua Hospital affiliated to Shanghai University of TCM, has been engaged in clinical and scientific research on the prevention and treatment of cardiovascular diseases with TCM. Professor Zhou Duan believes that on the premise of distinguishing different phases of the disease, the treatment of CHF should replenish Qi and invigorate blood, promote diuresis, nourish Yin, treat heart lung and kidney at the same time, protect the function of the spleen and stomach and take care of other illness as well. This article briefly reviewed relevant content for reference in clinical application.

  • Yanan ZHANG, Siriguleng, Hongxin YANG, Xiaobin GUO
    World Clinical Drug. 2023, 44(10): 1017-1021.

    The deterioration of chronic heart failure (CHF) not only reduces the quality of life of patients, increases the risk of hospitalization and death, but also imposes a heavy burden on healthcare resources. In order to better manage CHF, the Heart Failure Association of the European Society of Cardiology has developed a new clinical consensus statement in 2023, updating the definition, clinical characteristics, management, and prevention of CHF deterioration. The consensus highlights the importance of diuretics, and intravenous, oral or combined diuretics should be selected depending on the severity of the patient. It also emphasizes the importance of early and rapid administration of guideline recommended medical therapies to prevent first deterioration and repeated exacerbations of heart failure. In order to relieve the medical pressure and meet the needs of patients for timely treatment, it is recommended to carry out hierarchical diagnosis and treatment for patients, mild to moderate patients in emergency or outpatient treatment, severe patients need to choose hospital treatment. This article provided a brief interpretation of the relevant content in order to provide reference for the clinical management of CHF.

  • Lixin ZHANG, Yongli LIANG, Siriguleng, Li ZHANG, Yanan ZHANG, Wudan, Hongxin YANG
    World Clinical Drug. 2023, 44(10): 1022-1028.

    In 2022, the American College of Chest Physicians (ACCP) released the guidelines for the perioperative management of antithrombotic therapy. The guidelines mainly put forward antithrombotic recommendations for four clinical situations. Patients receiving vitamin K antagonists, heparin bridging, direct oral anticoagulants, antiplatelet drugs requiring surgery or invasive procedures, and perioperative laboratory testing were advised. This article compared with previous versions of the ACCP guidelines for perioperative antithrombotic therapy, and made a comprehensive interpretation of the guidelines combined with Shanghai Expert Consensus On Perioperative Management of Antithrombotic Patients Accepting Non-Cardiac Surgery (2021 Edition) and Chinese Guidelines for the Prevention and Treatment of Thrombotic Diseases, in order to provide references for the clinical application of antithrombotic drugs in perioperative period.

  • Zhaotang GONG, Wudan, Wurihan, Lixin ZHANG, Yanan ZHANG, Siriguleng
    World Clinical Drug. 2023, 44(10): 1029-1033.

    Antibacterial drug resistance is a severe challenge for the treatment of bacterial infectious diseases worldwide, especially in the treatment of ultra broad extended-spectrum β-lactamase-producing Enterobacteriaceae, carbapenem-resistant Enterobacteriaceae and drug-resistant Pseudomonas aeruginosa infected. In 2023, the Infectious Diseases Society of America provided guidance on the treatment of the three drug-resistant bacterial infections mentioned above based on updated evidence-based evidence. Based on the guidance and recommendations in domestic guidelines, this article reviewed the treatment for the three drug-resistant bacterial infections mentioned above, in order to provide clinical reference for the control and treatment of related diseases in China.

News